• 1. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 2. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines Pyrrolopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrrolopyridines

Introduction to 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine (CAS No. 878232-93-0)

3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine, identified by its Chemical Abstracts Service (CAS) number 878232-93-0, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its structural complexity and potential biological activity. This compound belongs to the pyrrolopyridine class, a scaffold that is widely recognized for its utility in drug discovery, particularly in the development of kinase inhibitors and other therapeutic agents.

The molecular structure of 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine features a fused ring system consisting of a pyrrole ring and a pyridine ring, with substituents that enhance its pharmacological properties. The presence of a benzyl group at the 3-position and a chloro group at the 4-position introduces specific electronic and steric characteristics that can modulate interactions with biological targets. Additionally, the methyl group at the 2-position further influences the compound's reactivity and binding affinity.

Recent advancements in medicinal chemistry have highlighted the importance of pyrrolopyridine derivatives in the design of small-molecule drugs. Studies have demonstrated that these compounds can exhibit inhibitory activity against various enzymes and receptors involved in cancer, inflammation, and other diseases. The structural motif of 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine makes it a promising candidate for further investigation in this context.

In particular, the chloro substituent at the 4-position of the pyrrolopyridine core is known to enhance binding interactions with protein targets by participating in hydrogen bonding or hydrophobic interactions. This feature has been exploited in the development of several lead compounds that have advanced into clinical trials. The benzyl group, on the other hand, can increase lipophilicity, which may improve membrane permeability and oral bioavailability—a critical factor in drug design.

Recent research has also explored the synthesis and functionalization of 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine to generate novel derivatives with enhanced pharmacological profiles. For instance, modifications at the 5-position or 6-position of the pyrrole ring have been investigated to optimize binding affinity and selectivity. These studies underscore the versatility of this scaffold and its potential for generating next-generation therapeutic agents.

The compound's significance extends beyond its structural features. Its synthesis involves multi-step organic reactions that showcase advanced techniques in heterocyclic chemistry. The preparation typically requires careful control of reaction conditions to ensure high yield and purity. Given its complexity, researchers have developed efficient synthetic routes that leverage modern methodologies such as transition metal catalysis or microwave-assisted synthesis to streamline production.

From a computational chemistry perspective, virtual screening and molecular docking studies have been employed to evaluate the binding potential of 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine with target proteins. These studies have provided valuable insights into its interactions with enzymes such as kinases or proteases, which are key players in many disease pathways. The results from these simulations have guided experimental efforts toward optimizing lead compounds for therapeutic applications.

The pharmacokinetic properties of 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine are also under investigation to assess its suitability for clinical use. Parameters such as solubility, stability, and metabolic clearance are critical factors that determine whether a compound can progress from preclinical to clinical development. Preliminary data suggest that modifications to the molecular structure can significantly impact these properties, offering opportunities to improve drug-like characteristics.

In conclusion, 3-Benzyl-4-chloro-2-methyl-1H-pyrrolo[3,2-c]pyridine (CAS No. 878232-93-0) represents an intriguing example of how structural innovation in heterocyclic chemistry can lead to novel pharmacological entities. Its unique combination of substituents and scaffold architecture positions it as a valuable tool for drug discovery efforts aimed at addressing unmet medical needs. As research continues to uncover new biological functions and synthetic strategies for this class of compounds, their potential applications are expected to expand further.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)